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ABSTRACT
Over the past two decades, there has been a rapid increase in the number of drugrelated deaths in the United States as a result of the current opioid epidemic (Capper et
al., 2018). In 2016, the number of deaths caused by drug overdoses in the United States
was at least 63,000 (Ashburn, 2016). During the same year, Pennsylvania had the third
highest percentage of drug overdose death rates in the country (Multiple cause of death
1999–2017, 2018). A division of drug abuse prevention policy present among 49 out of
50 states are programs known as Prescription Drug Monitoring Programs (PDMPs)
(Weber, 2019). These programs are statewide electronic databases that track all
controlled substance prescriptions. Although PDMPs were introduced to decrease the
prescription rate and the amount of doctor shoppers in each state, only four states have a
must-use mandate requiring practitioners to use PDMPs. All other states without a mustuse mandate significantly underutilize PDMPs—Pennsylvania being one state without a
must-use mandate. The objective of this study is to evaluate the impact of PDMPs on
drug-related deaths, prescription rates, doctor shoppers, and other trends related to the
opioid epidemic in the United States. The results from the four states with must-use
mandates, Ohio, Kentucky, Tennessee, and New York, suggest successful outcomes from
PDMPs. Therefore, it is suggested that future directives in Pennsylvania and Philadelphia
should use these data to implement a must-use mandate of their own to follow similar
trends. A strong initiative taken towards initiating must-use mandates of PDMPs is
necessary to reduce prescribing rates and slow the rapid rate of increase of drug-related
deaths in the United States.
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BACKGROUND
I.

Background
The number of drug overdose deaths continues to rise in the United States. The

CDC reports approximately 192 drug overdose deaths every day (Multiple cause of death
1999—2017, 2018). In 2017, overdose deaths involving opioids specifically accounted
for nearly 68% of all drug overdose deaths. Additionally, the state that has the third
highest rate of death because of drug overdose (44.3 per 100,000) is: Pennsylvania
(Multiple cause of death 1999–2017, 2018). Philadelphia is the leading district in
Pennsylvania for overdose deaths at 60 deaths per 100,000 deaths, which is greater than
the state average (The Opioid Threat in Pennsylvania, 2018). Deaths by drug overdoses
continue to follow a 4-fold increase which has occurred in Philadelphia in recent years
(Capper et al., 2018). Although there has been a rise in implementation of health care
policy and interventions to combat the opioid epidemic, further changes and initiatives
are necessary to continue to decrease opioid prescribing rates.
II.

Regulating Opioid Prescribing Rates
Other states, such as California, have implemented comprehensive programs

which have significantly decreased opioid prescribing rates. For example, the Kaiser
Permanente of Southern California group implemented a program to assess the necessity
of prescribing opioid medications before prescribing the drug. Among the physicians
following these guidelines, Kaiser Permanente reported a 30% reduction in prescribing
opioids in high doses and a 95% reduction in prescribing brand name opioidacetaminophen products. These programs include monitoring the adherence to
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prescribing and dispensing policies, patient follow-up, and increased use of electronic
health records. The underlying goal is to transform the treatment and outlook of chronic
pain to reduce unnecessary prescriptions (Losby, Hyatt, Kanter, Baldwin, Matsuoka,
2017).
According to the CDC, the likelihood of long-term use of opioids increases based
on the duration of the initial prescription (Shah, Hayes, Martin, 2017). Specifically, the
chances of long-term use increases after three to five days of taking a prescription.
Therefore, between 2015 and 2017, 33 states, including Pennsylvania, passed forms of
legislation to regulate the opioid epidemic by limiting prescribing practices. Pennsylvania
passed a bill in 2016 that limits first-time opioid prescriptions to seven days, which is the
most common number of days among the 33 states (Shah, Hayes, Martin, 2017).
Another branch of prevention policy present among 49 out of 50 states are
Prescription Drug Monitoring Programs (PDMPs) (Weber, 2019). These programs are
statewide electronic databases that track all controlled substance prescriptions. These
programs improve patient safety by allowing clinicians to identify patients who are
receiving opioid prescriptions from numerous providers, calculate the total amount of
opioids prescriber per day (in MME/day), and identify patients who are being prescribed
other drugs that can increase risk of using opioids (Prescription drug monitoring
programs (PDMPs)). Although the impact of the state-level PDMPs were mixed, states
with more comprehensive monitoring resulted in larger reductions in overdoses compared
to states with less comprehensive monitoring among Medicare beneficiaries (Weber,
2019; Moyo et al., 2017).
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Several states have recently enacted and modified their PDMPs which most
probably contributed to the emerging data that suggest fewer patients receiving opioids
with lower initial doses which result in a shorter duration of treatment of opioids (31, 44).
Pennsylvania did not have an active PDMP until recently when legislation was passed in
August 2016 (Ashburn, 2016). As of September 2019, Pennsylvania shares data from the
PDMPs with 21 other states, military health systems and D.C. Interstate Sharing to
provide a comprehensive background check of patients in need of opioids (Prescription
drug monitoring program (PDMP), 2019).
The introduction of PDMPs has supporting evidence of decreased opioid
prescription rates among the states and hospitals that are readily using them. They have
been identified as a useful tool to reduce opioid prescription abuse. However, since
PDMPs have recently been incorporated into health systems, they are being underutilized
by providers because there are barriers to their use. Additionally, 25% of primary care
physicians surveyed by Johns Hopkins University stated that they were not aware they
had a PDMP (Rutkow, Turner, Lucas, Hwang, Caleb, Alexander, 2015). As suggested by
the Johns Hopkins researchers, there are a few ways to strengthen PDMPs such as
increasing legal mandates, investing in prescriber education, and enhancing ease of
access to and use of the programs (Rutkow, Turner, Lucas, Hwang, Caleb, Alexander,
2015).
One form of legislation, which was mandated to increase the use of PDMPs, is a
must-use mandate for PDMPs. Only four states have implemented must-use mandates:
Ohio, Kentucky, Tennessee, and New York (Haffajee, Jena, & Weiner, 2015). This

5

mandate requires the use of PDMPs statewide with penalties for underutilization.
Therefore, every practitioner and pharmacist in the four states with must-use mandates
must query the system before prescribing and opioid and report the prescription into the
PDMP system within one business day of the prescription (Haffajee, Jena, & Weiner,
2015).
In recognition of the increasing success of reducing opioid prescription rates
through the use of PDMPs, legislators should continue to strengthen these programs,
especially in the city of Philadelphia, to reduce the high rate of overdose deaths.
Additionally, the expansion of sharing PDMP data with more states could also result in a
more comprehensive view of each patient. By advocating for increased use of PDMPs
through legislation, the amount of overdose deaths in Philadelphia could potentially
decrease. To address the advancement of PDMPs in the state of Pennsylvania, starting at
the city council level will encourage state-level legislative change.
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RESEARCH STRATEGIES
This capstone analyzes reported trends in data regarding prescription rates in
states that have implemented a must-use mandate for PDMPs. Multiple studies which
investigate the performance and success of PDMPs analyze all 49 states collectively
instead of focusing on the states that mandatorily use PDMPs. By comparing the four
states that have must-use mandates with the remaining 45 states which don’t have a mustuse mandate, the results become skewed. States with must-use mandates are required to
produce an annual report with the statistics concerning trends related to the opioid
epidemic. Therefore, in this investigation, the annual PDMP reports from the four states
with must-use mandates will be studied.
A systematic literature review was conducted to determine the impact of
implementing PDMPs. The Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRIMSA) guidelines were used to improve the quality and consistency of the
identified reports and studies for this capstone paper. The following inclusion criteria
were used to identify reports and studies related pertaining to this topic:
1. English-language studies performed in the United States between 2010 and
2020 through the “most recent” searching filter.
2. Individual state level reports of usability, utilization, and outcomes of PDMPs
3. Individual state level reports of opioid prescription rates
4. Must identify the use of PDMPs by the state in the report
Data related to the impact of trends related to opioid prescription rates were
summarized and analyzed.
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RESULTS
Out of all states investigated in this study, 49 out of 50 states have implemented
the use of PDMPs. Out of the 49 states, only 4 states have must-use mandates for
providers to actually utilize PDMPs in practice: Ohio, Kentucky, Tennessee, and New
York. All other states allow voluntary reporting of prescriptions in PDMPs, including
Pennsylvania. Pennsylvania is only required to query the system before prescribing an
opioid (PDMP Annual Report 2016-2017, 2020). Compared to the states with a must-use
mandate which are required to report prescriptions into the PDMP, Pennsylvania is not
required to report prescriptions into the PDMP daily. Therefore, the statistics regarding
the PDMP in Pennsylvania only report an increase in the number of queries since the
PDMP has been implemented. Data concerning the effect on prescribing rates, doctor
shoppers, and other trends associated with the opioid epidemic in Pennsylvania are not
well known. This may be associated with the fact that Pennsylvania does not have a
must-use mandate for PDMPs. The following results will describe the trends of opioid
prescription rates and doctor shopping related to the opioid epidemic in the four states
that have must-use mandates for PDMPs.
Ohio
Ohio developed a drug monitoring program specific to the state entitled the “Ohio
Automated Rx Reporting System” (OARRS). This database serves as the only statewide
electronic database which stores all controlled substance dispensing and personal
furnishing information. According to the OARRS Annual Report, Ohio continues to
advance in safe prescribing methods of opioids. Additionally, it indicates that the total
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number of opioid doses decreased from 793 million in 2012 to 415 million in 2019 and
the total number of opioid prescriptions decreased by 5 million during the same period
of time—these differences are a 48 percent and 40 percent decrease, respectively (Figures
1, 2). As seen in Figure 3, the average daily MED per instance of personal furnished
opioids by Ohio prescribers has also decreased since 2010 (Ohio Automated Rx
Reporting System 2019 Annual Report, 2019). As MED decreases, the less likely
an adverse event occurs.
The overall mandate for PDMPs requires that doctor’s query the program before
prescribing opioids—again, the purpose is to avoid doctor shopping and reduce opioid
prescription rates. The number of queries in OARRs increased from 1.78 million to over
240 million over the course of 9 years. Contrastingly, the number of reported doctor
shoppers decreased 88 percent over the same 9-year period (Figures 7, 8) (Ohio
Automated Rx Reporting System 2019 Annual Report, 2019).
Kentucky
Similar to Ohio, Kentucky also designed its own prescription monitoring program
entitled “Kentucky All Schedule Prescription Electronic Reporting” otherwise known as
KASPER. The CDC reported Kentucky as a success in reducing opioid prescriptions due
to the mandatory use of KASPER and regulation of pain clinics across the state. The
Kentucky Office of Drug Control Policy states that since Kentucky mandated the use of
KASPER in 2012, there has been a 22% decrease in the number of opioid doses
prescribed since 2011 (Figure 5) (Opioid Abuse in Kentucky, 2019). According to the
2019 KASPER Indicator Progress Report, the rate of Kentucky Multiple Provider
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Episodes for Prescription Opioids, otherwise known as doctor shopping, has steadily
decreased since 2014. The percentage of Kentucky Patients Receiving more than an
average daily dose of ≥ 100 MMEs of Opioid Analgesics went from 39.39% in 2014 to
14.1% in 2018 (Akers, Quesinberry, & Bunn, 2019).
Tennessee
Tennessee also has its’ own prescription drug monitoring program called the
Tennessee Controlled Substance Monitoring Database (CSMD) which provides health
care practitioners with a patient’s prescription history. Mandatory registration in the
CSMD started in 2013 but became more utilized in 2016 when data were required to be
submitted every day (Tennessee Department of Health, 2020). The Tennessee
Department of Health released the 2020 annual CSMD report which contained the
following key findings:








The number of prescriptions for opioids decreased by 38% since 2012.
The average MME prescribed and dispensed to patients statewide decreased by
53% since 2012.
The number of people prescribed more than 120 MME/day decreased by 52%
since 2012.
The number of potential doctor shoppers detected by the system decreased by
89% since 2011 (Figure 6).
The number of CSMD searches and queries has increased by 603% since 2012
and continues to rise.
The number of controlled substance prescriptions entered to the CSMD has
decreased by 11% since 2013.
On average, there was 1 search for every 1.3 prescriptions in Tennessee in 2019,
compared to 1 search for every 12 prescriptions in 2011.
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New York
New York state mandated the use of their Prescription Monitoring Program
registry (PMP) in 2012, which requires any practitioner writing a prescription to report it
in the system. The following trends have resulted:





A 22% decreased in the rate of opioid prescriptions between 2015 and 2018.
The number of patients who received opioids from 5 or more prescribers, at five
or more pharmacies, otherwise known as doctor shoppers, decreased significantly
from 8.7 per 100,00 in 2015 to 1.3 per 100,000 in 2018 (NYS Department of
Health, 2019).
Practitioners in New York wrote 37.8 opioid prescriptions per 100 persons in
2017, which was one of the lowest rates in the country for that year. The average
rate of opioid prescriptions per 100 persons was 58.7 in the United States in 2017
(NYS Department of Health, 2019).
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DISCUSSION
The data obtained from each state’s reports indicate successful utilization of
PDMPs in reducing opioid prescription rates. These data provide evidence that
comprehensive use of PDMP mandates for practitioners increase PDMP use and
influence opioid prescribing rate trends. Without the implementation of the must-access
mandates in these states, it seems unlikely that these trends in opioid prescription rates
and doctor shopping would have occurred in a similar manner. The start of opioid
substance use disorder from prescription opioids is ongoing, however it can be reduced
through increased implementation and regulation of how opioids are prescribed, when
they are prescribed, and who they are prescribed to. These factors are accounted for
through PDMPs.
Although Pennsylvania has a PDMP in place, it is not required for prescribers to
check the PDMP before an initial opioid prescription and prescribers are not required to
conduct subsequent interval checks after a prescription has been made. Through the
aforementioned trends in the states that have implemented mandatory utilization of
PDMPs, it seems necessary for a nationwide mandate to encourage similar trends in the
remaining states, Pennsylvania being one of them. The demand for decreasing opioid
prescription rates in Pennsylvania is high due to the ongoing placement of Pennsylvania
as the third leading state in the country for the number of opioid deaths per year.
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RECOMMENDATIONS FOR FUTURE STUDIES
The data described above provide evidence that mandating the use of PDMP by
practitioners nationwide could contribute to an overall reduction in prescribing opioids
and doctor shopping in each state. It is recommended that advocates for combating the
opioid epidemic in Pennsylvania should work with health care professionals and
associated stakeholders to gather and present the evidence needed to encourage policy
change in the Pennsylvania General Assembly. The results of this investigation can be
presented to various state level legislators to develop a must-use mandate for PDMPs in
Pennsylvania. However, if it is possible to start at the city level, it is recommended to
implement a must-use PDMP mandate in the city of Philadelphia. This city should adopt
this mandate since it is reported as the district with the greatest number of opioid deaths
in Pennsylvania.
PDMPs are useful systems for practitioners in making informed prescribing
decisions in practice. It is necessary for other states to recognize the degree of operability
and meaningful results that come from this tool. Therefore, it is critical to talk to
legislators, government officials, local residents, and members of the health care
community to inform them of the systematic benefit of using PDMPS to improve one
aspect of the multifaceted opioid epidemic that Philadelphia is experiencing, along with
the rest of the country.
Future studies should continue to collect data from other states that have mandates
for PDMP use to statistically analyze the drastic statistical differences seen from PDMPs.
Many of the studies that have similar comparisons fail to acknowledge the differences in
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states that have a must-access mandate and therefore the results are skewed. The United
States are on the road to mandating PDMP usage nationwide in the future, however
future studies can be a catalyst for this process.
Finally, future studies should investigate the number of practitioners and
pharmacists aware of the value and results of using PDMPs. As of now, many providers
are unaware and underutilize PDMPs which caused the need for the must-use mandates.
By investigating these trends, future studies can combine this information with the trends
of states that have must-use mandates to show how utilization increases after mandates
are implemented. These data can be used when discussing with legislators to influence
their view and understanding about the need for a new mandate.
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APPENDIX A
Relative Definitions
Opioids- A class of pain-relieving medications used to reduce the level of pain a person
is experiencing. Prescription opioids are prescribed to people undergoing moderate to
severe pain due to chronic pain or pain occurring after surgery or injury. The term
“opioid” encompasses natural, synthetic, or semi-synthetic chemicals that have similar
pain-relieving effects. These chemicals bind to opioid receptors throughout the body and
decrease the amount of pain felt (Commonly Used Terms). Examples of opioids include:
Natural Opioids: Morphine and Codeine
Semi-synthetic Opioids: oxycodone, hydrocodone, hydromorphone, and
oxymorphone
Synthetic Opioids: Methadone, Tramadol, and Fentanyl
Opioid Use Disorder (OUD)- According to the DSM-5, OUD is a problematic pattern of
opioid use that causes significant impairment or distress. The diagnosis for OUD is
dependent on a variety of factors such as: the amount of opioid intake, unsuccessful
efforts to cut down or control opioid use, desire to use opioids, social or interpersonal
problems caused by the effects of opioids, failure to maintain social, occupational, and
recreational activities, recurrent use of opioids, and exhibiting tolerance of or withdrawal
from opioids (Module 5: Assessing and addressing opioid use disorder (OUD)).
Opioid Epidemic or Opioid Crisis- The increased use of opioid drugs resulting in
increased drug overdose deaths in the United States (Commonly Used Terms).
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Medication-assisted treatment (MAT)- The combination of medication (such as
methadone, buprenorphine, or naltrexone), counseling, and behavioral therapies used to
treat opioid use disorder (Commonly Used Terms).
Illicit drugs- Drugs used for non-medical related reasons that are prohibited by law.
Opioids such as heroin and illicitly manufactured fentanyl fall under this category
(Commonly Used Terms).
Morphine Equivalent Dose (MED)- the total amount of opioid medications, converted
to a common unit (milligrams of morphine), that a patient currently has access to based
on the information reported by prescribers and pharmacists to OARRS. Morphine is
known to be the standard for treatment of moderate to severe pain and use used a
reference point (Ohio Automated Rx Reporting System 2019 Annual Report, 2019).
Personal Furnished- The distribution of drugs by a prescriber to the prescribers’ patients
for use outside the prescriber’s practice setting (Ohio Automated Rx Reporting System
2019 Annual Report, 2019).
Doctor Shopper- An individual receiving a prescription for a controlled substance from
five or more prescribers in one calendar month (Ohio Automated Rx Reporting System
2019 Annual Report, 2019).
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APPENDIX B

Figure 1. Opioid Solid Doses Dispensed to Ohio Patients, by Year (Ohio Automated Rx
Reporting System 2019 Annual Report, 2019).

Figure 2. Opioid Prescriptions Dispensed to Ohio Patients, by year (Ohio Automated Rx
Reporting System 2019 Annual Report, 2019).
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Figure 3. OARRS Queries, by year (Ohio Automated Rx Reporting System 2019 Annual
Report, 2019).

Figure 4. Total Doctor Shoppers, by year (Ohio Automated Rx Reporting System 2019
Annual Report, 2019).
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Figure 5. Annual Opioid Analgesic Doses as Reported to KASPER (Akers, Quesinberry,
& Bunn, 2019).

Figure 6. Potential Doctor and Pharmacy Shoppers identified by CSMD (Tennessee
Department of Health, 2020).

